IQVIA Holdings Inc. $IQV Shares Sold by L. Roy Papp & Associates LLP

L. Roy Papp & Associates LLP trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 16.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,927 shares of the medical research company’s stock after selling 777 shares during the quarter. L. Roy Papp & Associates LLP’s holdings in IQVIA were worth $619,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of IQV. Everpar Advisors LLC increased its position in IQVIA by 4.6% in the 2nd quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 62 shares during the period. Ballentine Partners LLC increased its position in IQVIA by 4.9% in the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company’s stock valued at $260,000 after acquiring an additional 69 shares during the period. Independent Advisor Alliance increased its position in IQVIA by 4.2% in the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock valued at $318,000 after acquiring an additional 72 shares during the period. Nemes Rush Group LLC increased its position in IQVIA by 15.0% in the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company’s stock valued at $109,000 after acquiring an additional 81 shares during the period. Finally, Forte Capital LLC ADV increased its position in IQVIA by 0.3% in the 2nd quarter. Forte Capital LLC ADV now owns 26,809 shares of the medical research company’s stock valued at $4,225,000 after acquiring an additional 92 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 5,800 shares of the company’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider owned 27,178 shares of the company’s stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

IQV opened at $203.16 on Friday. The stock has a market cap of $34.54 billion, a P/E ratio of 29.40, a P/E/G ratio of 2.20 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The stock’s 50 day simple moving average is $188.70 and its 200 day simple moving average is $168.15. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $237.34.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to analysts’ expectations of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IQV. Truist Financial boosted their price target on IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a research report on Wednesday, July 23rd. Robert W. Baird boosted their target price on IQVIA from $159.00 to $196.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 23rd. Mizuho boosted their target price on IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Redburn Partners set a $214.00 target price on IQVIA in a research report on Wednesday, September 3rd. Finally, Evercore ISI boosted their target price on IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a research report on Wednesday. Nineteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $236.45.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.